AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31972580 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of smoking, body mass index, and anemia
Number of subjects: 160
Study 31972580 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of handheld Dopplers (available in 66% of facilities)
Number of subjects: 160
Study 31972580 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal wound care training for personnel (61% indicated no training)
Number of subjects: 160
Study 30218229 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide eugenol control cement (ZOE)
Number of subjects: 50
Study 30218229 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine™
Number of subjects: 50
Study 30218229 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer cement (GIC)
Number of subjects: 50
Study 30218229 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA (Mineral Trioxide Aggregate)
Number of subjects: 50
Study 30218229 — intervention group
Group type: EXPERIMENTAL
Intervention: Portland cement
Number of subjects: 50
Study 29719839 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 liters of irrigation
Number of subjects: 204
Study 29719839 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 liters of irrigation
Number of subjects: 204
Study 29719839 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 liters of irrigation
Number of subjects: 204
Study 29719839 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality rate
Number of subjects: 204
Study 26294138 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic waves (TWs)
Number of subjects: 20
Study 26294138 — intervention group
Group type: COMPARATOR
Intervention: No triphasic waves (non-TWs)
Number of subjects: 20
Study 24481723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial bone marrow cell injection
Number of subjects: 16
Study 24481723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 22315948 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily
Number of subjects: 600
Study 22315948 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 600
Study 19890125 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 2203
Study 19890125 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 2203
Study 17728426 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg/day for the first 4 weeks, then 30 mg/day for the following 4 weeks)
Number of subjects: 56
Study 17728426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 17728426 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (for female patients with menstrual disturbances)
Number of subjects: 56
Study 17728426 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for female patients with menstrual disturbances)
Number of subjects: 56
Study 17728426 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 56
Study 15316907 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change interventions in cancer screening research
Number of subjects: 0
Study 15316907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer screening strategies
Number of subjects: 0
Study 15316907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer screening behaviors
Number of subjects: 0
Study 15316907 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized designs
Number of subjects: 0
Study 11936356 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin-bonded Dacron grafts
Number of subjects: 0
Study 11936356 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard grafts)
Number of subjects: 0
Study 11936356 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (rifampicin-bonded Dacron grafts)
Number of subjects: 0
Study 9604598 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum retinol levels in infants and adults; specific levels not detailed; analysis of cord blood, infantile and adult levels of retinol.
Number of subjects: 0
Study 9604598 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum retinol levels in women (pregnant or non-pregnant)
Number of subjects: 0
Study 9604598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off level for deficiency
Number of subjects: 0
Study 7506675 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF
Number of subjects: 22
Study 7506675 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF
Number of subjects: 22
Study 7506675 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐3
Number of subjects: 22
Study 2574766 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxpentifylline (500 mg over 4 h) after 100 ng endotoxin injection
Number of subjects: 10
Study 2574766 — intervention group
Group type: COMPARATOR
Intervention: Control (100 ng endotoxin injection without oxpentifylline)
Number of subjects: 10
Study 1183792 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Heparin (Liquemin Roche) subcutaneously, 5000 units 2 hours pre-operatively and every 12 hours until the eighth post-operative day
Number of subjects: 458
Study 1183792 — intervention group
Group type: COMPARATOR
Intervention: Oral anti-coagulants (Sintrom) from the second post-operative day to complete ambulation, maintaining quick test between 20 and 30%
Number of subjects: 458
Study 1183792 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Heparin
Number of subjects: 458
Study 1183792 — intervention group
Group type: COMPARATOR
Intervention: Oral anti-coagulants (Sintrom)
Number of subjects: 458
Study 30915723 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental calcium with or without vitamin D
Number of subjects: 0
Study 30915723 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation
Number of subjects: 0
Study 30915723 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D co-administration
Number of subjects: 0
Study 28633157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ventilation management for patients at increased risk of PPCs
Number of subjects: 9864
Study 28633157 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative ventilation management for patients at low risk of PPCs
Number of subjects: 9864
Study 28633157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory management (Tidal Volume and PEEP)
Number of subjects: 9864
Study 26156625 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin (2.5 mg)
Number of subjects: 134
Study 26156625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (1 or 2 mg)
Number of subjects: 134
Study 24511717 — intervention group
Group type: EXPERIMENTAL
Intervention: LED phototherapy
Number of subjects: 50
Study 24511717 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 50
Study 21971374 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg
Number of subjects: 81
Study 21971374 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg
Number of subjects: 81
Study 21971374 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 81
Study 21971374 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin 200 IU
Number of subjects: 81
Study 21971374 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 400 IU
Number of subjects: 81
Study 21971374 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (Control)
Number of subjects: 81
Study 18452434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream containing retinol, lactose and glycolic acid applied twice daily for 12 weeks
Number of subjects: 40
Study 18452434 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied twice daily for 12 weeks
Number of subjects: 40
Study 16670692 — intervention group
Group type: EXPERIMENTAL
Intervention: Imedeen Prime Renewal (two tablets twice daily for 6 months)
Number of subjects: 80
Study 16670692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets twice daily for 6 months)
Number of subjects: 80
Study 14605896 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow cooling conditions (above 10 s to reach TC=0.5 degrees C)
Number of subjects: 10
Study 14605896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast cooling conditions (below 10 s to reach TC=0.5 degrees C)
Number of subjects: 10
Study 14605896 — intervention group
Group type: EXPERIMENTAL
Intervention: General linear model approach
Number of subjects: 10
Study 11680668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin (175 IU/kg)
Number of subjects: 425
Study 11680668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin (4,500 IU)
Number of subjects: 425
Study 11680668 — intervention group
Group type: COMPARATOR
Intervention: Control (Heparin)
Number of subjects: 425
Study 11680668 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (40 mg)
Number of subjects: 425
Study 9226735 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 5222, 100 micrograms
Number of subjects: 3
Study 7964961 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (day 1, 0.2 mg/kg i.v.; days 2 through 6, 8 mg orally)
Number of subjects: 445
Study 7964961 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose alizapride (day 1, 100 mg i.v. and 4 x 50 mg orally; days 2 through 6, 4 x 50 mg orally)
Number of subjects: 445
Study 7964961 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling the dose of tropisetron (10 mg once daily)
Number of subjects: 445
Study 7964961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study 3597568 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy intervention (approximately six sessions within 3-5 months of bereavement)
Number of subjects: 45
Study 3597568 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 29059139 — intervention group
Group type: EXPERIMENTAL
Intervention: HARRL (with lidocaine)
Number of subjects: 170
Study 29059139 — intervention group
Group type: COMPARATOR
Intervention: HAJU (without lidocaine)
Number of subjects: 170
Study 29059139 — intervention group
Group type: EXPERIMENTAL
Intervention: HARRL
Number of subjects: 170
Study 29059139 — intervention group
Group type: COMPARATOR
Intervention: HAJU
Number of subjects: 170
Study 29122785 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoxuekang
Number of subjects: 240
Study 29122785 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinnaoshutong (XNST)
Number of subjects: 240
Study 29122785 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuesaitong (XST)
Number of subjects: 240
Study 29122785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 25775674 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon
Number of subjects: 60
Study 25775674 — intervention group
Group type: COMPARATOR
Intervention: Uncoated balloon
Number of subjects: 60
Study 23294549 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA-SC self-administration
Number of subjects: 55
Study 23294549 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA-SC self-administration proficiency ratings
Number of subjects: 55
Study 21422325 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based intervention (DVD and 2 postcard reminders)
Number of subjects: 930
Study 21422325 — intervention group
Group type: COMPARATOR
Intervention: Brochures-only control
Number of subjects: 930
Study 18327010 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg IM for 6 weeks followed by 15 mg IM for 6 weeks (group 1)
Number of subjects: 20
Study 18327010 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg IM weekly for 12 weeks (group 2)
Number of subjects: 20
Study 18327010 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 20
Study 16458955 — intervention group
Group type: EXPERIMENTAL
Intervention: Troop and Internet program to increase physical activity skills, self-efficacy, and goal-setting over 9 weeks
Number of subjects: 473
Study 16458955 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 473
Study 12521624 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS guidance
Number of subjects: 269
Study 12521624 — intervention group
Group type: COMPARATOR
Intervention: ANGIO guidance
Number of subjects: 269
Study 11044230 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment blood pressure measurements
Number of subjects: 163
Study 11044230 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment blood pressure measurements (120 minutes)
Number of subjects: 163
Study 11044230 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril treatment
Number of subjects: 163
Study 11044230 — intervention group
Group type: COMPARATOR
Intervention: Conventional antihypertensive therapy
Number of subjects: 163
Study 8844941 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of organ donor card-signing through persuasive communication strategies
Number of subjects: 0
Study 1735484 — intervention group
Group type: EXPERIMENTAL
Intervention: Parlodel SRO (5 mg/d for first 15 days, then 10 mg/d for 1 month; variable doses up to 20 mg/d for 1 year)
Number of subjects: 16
Study 1735484 — intervention group
Group type: COMPARATOR
Intervention: Parlodel (5 mg/d for first 15 days, then 10 mg/d for 1 month)
Number of subjects: 16
Study 1735484 — intervention group
Group type: EXPERIMENTAL
Intervention: Parlodel SRO (1 year treatment)
Number of subjects: 16
Study 6371278 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine mesylate, 0.5 mg, plus heparin sodium, 5,000 IU
Number of subjects: 880
Study 6371278 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine mesylate, 0.5 mg, plus heparin sodium, 2,500 IU
Number of subjects: 880
Study 6371278 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin sodium, 5,000 IU alone
Number of subjects: 880
Study 6371278 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine mesylate, 0.5 mg alone
Number of subjects: 880
Study 6371278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 880
Study 31206083 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of zinc sulfate daily for 14 days
Number of subjects: 4500
Study 31206083 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of zinc sulfate daily for 14 days
Number of subjects: 4500
Study 31206083 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of zinc sulfate daily for 14 days
Number of subjects: 4500
Study 31206083 — intervention group
Group type: COMPARATOR
Intervention: WHO/Unicef Integrated Management of Childhood Illness standard of care
Number of subjects: 4500
Study 28807645 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention (226 participants)
Number of subjects: 338
Study 28807645 — intervention group
Group type: COMPARATOR
Intervention: Control group (112 participants)
Number of subjects: 338
Study 28807645 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 338
Study 27779461 — intervention group
Group type: EXPERIMENTAL
Intervention: lercanidipine/enalapril
Number of subjects: 56
Study 27779461 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide/enalapril
Number of subjects: 56
Study 27779461 — intervention group
Group type: COMPARATOR
Intervention: enalapril/amlodipine
Number of subjects: 56
Study 27779461 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 56
Study 25007690 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural butorphanol 0.04 mg/kg
Number of subjects: 80
Study 25007690 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine 0.06 mg/kg
Number of subjects: 80
Study 22748873 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix 240 mg for 1 month followed by monthly maintenance doses of 80 or 160 mg
Number of subjects: 0
Study 22748873 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide 7.5 mg/month
Number of subjects: 0
Study 20131032 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianggan Capsule (QGC)
Number of subjects: 88
Study 20131032 — intervention group
Group type: COMPARATOR
Intervention: Polyene phosphatidylcholine capsule (PPC)
Number of subjects: 88
Study 17418289 — intervention group
Group type: EXPERIMENTAL
Intervention: Early abciximab administration (in the emergency room)
Number of subjects: 210
Study 16271912 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg daily (n = 120)
Number of subjects: 224
Study 16271912 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 750 mg daily and Lansoprazole 30 mg daily (n = 122)
Number of subjects: 224
Study 12398965 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg twice daily)
Number of subjects: 20
Study 12398965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12398965 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (age- and gender-matched with negative treadmill exercise tests)
Number of subjects: 20
Study 9972551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience inductions
Number of subjects: 603
Study 9972551 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 603
Study 9972551 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback about driving (Study 4)
Number of subjects: 603
Study 7752918 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (maximum 12 mg/d)
Number of subjects: 12
Study 7752918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2182169 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral pulse methotrexate
Number of subjects: 53
Study 2182169 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 53
Study 527341 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestasert IUD
Number of subjects: 295
Study 527341 — intervention group
Group type: COMPARATOR
Intervention: Copper 7 IUD
Number of subjects: 295
Study 527341 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Progestasert and Copper 7 IUDs
Number of subjects: 295
Study 527341 — intervention group
Group type: COMPARATOR
Intervention: Comparison of premenstrual and intermenstrual cramps
Number of subjects: 295
Study 31014386 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde inferior vena caval perfusion (RIVP) combined with selective antegrade cerebral perfusion (ACP) under moderate hypothermia
Number of subjects: 636
Study 31014386 — intervention group
Group type: COMPARATOR
Intervention: Selective antegrade cerebral perfusion (ACP) under moderate hypothermia
Number of subjects: 636
Study 28781115 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading the screening leaflet
Number of subjects: 226
Study 28781115 — intervention group
Group type: COMPARATOR
Intervention: Not reading the screening leaflet
Number of subjects: 226
Study 27292104 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Number of subjects: 326
Study 27292104 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 326
Study 24613159 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection prevention measures including chlorhexidine-alcohol skin preparation and avoidance of BITA grafts in obese diabetic women.
Number of subjects: 1001
Study 24613159 — intervention group
Group type: COMPARATOR
Intervention: BITA grafting in obese diabetic women.
Number of subjects: 1001
Study 24613159 — intervention group
Group type: EXPERIMENTAL
Intervention: General infection prevention measures applied during CABG.
Number of subjects: 1001
Study 22300739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol 50,000 IU weekly
Number of subjects: 90
Study 22300739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 19543205 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI diet
Number of subjects: 12
Study 19543205 — intervention group
Group type: COMPARATOR
Intervention: High-GI diet
Number of subjects: 12
Study 17259573 — intervention group
Group type: EXPERIMENTAL
Intervention: DUI court
Number of subjects: 284
Study 17259573 — intervention group
Group type: COMPARATOR
Intervention: Traditional criminal court
Number of subjects: 284
Study 15242032 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP of 5 cmH2O
Number of subjects: 18
Study 15242032 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP adjusted to the patient's lower inflection point (LIP)
Number of subjects: 18
Study 15242032 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 12404693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (21 mg/day via transdermal patch)
Number of subjects: 10
Study 12404693 — intervention group
Group type: COMPARATOR
Intervention: Placebo (transdermal patch)
Number of subjects: 10
Study 12669739 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 100
Study 12669739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8674919 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with porfimer sodium and argon‐pumped dye laser
Number of subjects: 236
Study 8674919 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG laser therapy
Number of subjects: 236
Study 8674919 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 236
Study 1694421 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (15 mg/kg over 60 min)
Number of subjects: 12
Study 1694421 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin (15 mg/kg over 30 min)
Number of subjects: 12
Study 694800 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine (0.05%)
Number of subjects: 12
Study 694800 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (0.5%)
Number of subjects: 12
Study 694800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31838924 — intervention group
Group type: EXPERIMENTAL
Intervention: PRGF injection once
Number of subjects: 13
Study 31838924 — intervention group
Group type: EXPERIMENTAL
Intervention: PRGF injection thrice
Number of subjects: 13
Study 31298499 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care intervention implemented in 20 nursing homes over a six-month period
Number of subjects: 52
Study 31298499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 28040235 — intervention group
Group type: EXPERIMENTAL
Intervention: palonosetron 0.075mg
Number of subjects: 120